TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: serum Pro-BNP level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Amount of water evaporated
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distance between the Sural nerve and the Achilles tendon
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: success in selective bile duct cannulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Hip peak torque
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change from baseline for EQ-5D TTO score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change from baseline for EQ-5D linear rating scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change from baseline for physical functioning in everyday life (PF-10)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in 3-item Bleeding Index (BI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Tissue oxygen saturation score of gastric tube
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time needed to tracheal intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Healing rate of esophageal anastomosis leakage or perforation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Rate of clinically significant change in FVC and/or DLCO
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: OA/US Specificity of Benign Masses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: OA/US Sensitivity of Malignant Masses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax: peak plasma concentration after dosing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-∞: area under the concentration-time curve from 0 extrapolated to infinite time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tmax: time of peak plasma concentration of imeglimin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tolerance of intracerebral administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Maximum-tolerated dose of veliparib
Endpoint domain: Adverse events/effects
Primary endpoint: Dose-limiting toxicities of veliparib
Endpoint domain: Adverse events/effects
Primary endpoint: International Prostate Symptom Score (IPSS) Quality of Life (QoL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Maximum Flow Rate (Qmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postvoid Residual Volume (PVR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Results of skin test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Sagittal Plane Hip Moment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of women deciding to have BRCA testing
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Percentage of Responders When Accounting for Missing Central Laboratory Serum Potassium Data
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CMax of ROTIGOTINE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pyruvate levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Healthcare resources utilization
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Prevalence of advanced colorectal neoplasia or cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Physiological differences between obese patients with OHS and without OHS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NAA to Creatine (NAA/Cr) Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of primary hyperaldosteronism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Skin reaction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Rate of prophylaxis against venous thromboembolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Number of Participants Prescribed Antibiotics
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Participants Prescribed Antiviral Therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Average Adherence to Nutrition Sessions
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Average Adherence to Exercise Sessions
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Renal/patient survival at 2 years post-natally
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of time spent in target glucose range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percent Change in Serum Myostatin Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients starting iAluRil within 10 days post injury
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Dental Caries for Primary Molars Sound at Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dental Caries for All Primary Teeth Sound at Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subject incidence of treatment-emergent suicidal ideation and behavior as assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)
Endpoint domain: Adverse events/effects
Primary endpoint: Tacrolimus concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: acute and early late toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: VAS of radiating leg pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risks factors leading to sudden unexplained death in childhood (SUDC)
Endpoint domain: Mortality/survival
Primary endpoint: Lower urinary tract syndrome score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: SCORAD Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: serious adverse event (SAE) Rate
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of adverse event profile
Endpoint domain: Adverse events/effects
Primary endpoint: Objective radiological response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cellular quality of EUS-FNA specimens
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Histological quality of EUS-FNB specimens
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Buschke Reminding Test, learning index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Increase in coping skills
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Better psychological adjustment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Decreased parenting stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Overall Discrepancy Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Quartile Discrepancy Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Discrepancy Size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: End of Use Agreement: Number of Inhalers With an End of Use Agreement of 0
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mean rate of COPD exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of hospitalized patients
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Mean reduction value of available FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elevation of serum 25-hydroxyvitamin D levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Local, regional and distant tumor control rates
Endpoint domain: Mortality/survival
Primary endpoint: Disease-free and overall survival rates
Endpoint domain: Mortality/survival
Primary endpoint: Complication rates measured using the Common Toxicity Criteria for Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Relative Power of Event Related Desynchronization in µ et beta EEG bands
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Fatty acid composition of RBC membrane
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence Rates of Likely Acute Pancreatitis (Current Use Period)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence Rates of Likely Acute Pancreatitis (Recent Use Period)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence Rates of Likely Acute Pancreatitis (Past Use Period)
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of mutation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Viral response at week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Antibody Response to Vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rate of juvenile cataract patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmic outcomes
Primary endpoint: Sensitivity and specificity of Xpert TB/RIF tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Stress Test Results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Irritancy rating scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change from Baseline Virological measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from Baseline Immunological measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean Change in Severity of Morning Stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in axonal integrity and organization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: COVID-19 diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Potent COVID-19 sequelae
Endpoint domain: Adverse events/effects
Primary endpoint: Sleepiness score
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Decrease in viral load >= 1.0 log10 at 16 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive changes in CD4 count, weight, and Karnofsky Performance Score at 16 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in quality of life as determined monthly, using the MOS-HIV Health Survey
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number Adherent With the Intervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Delta height SDS every 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postpartum hemorrhage (blood loss >or= 500 mL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Drop in hemoglobin > 2 g/dL from pre to post-delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Vision test reliability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in the Lysholm joint function score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Degree of Lesion Filling (%Fill)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Repair Tissue Quality (T2 MRI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number and types of toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Excretion of radioactivity in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Excretion of radioactivity in feces
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of detected endometriotic lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma glucose area under the curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: AUC0-infinity of glyburide in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of glyburide in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCτ,ss of BI 1356 in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax,ss of BI 1356 in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of Borrelia Burgdorferi in Ticks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Participants With Adverse Event Related to the Application of Ticks
Endpoint domain: Adverse events/effects
Primary endpoint: Dual lead telemetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Hematology and chemistry parameters of clinical laboratory test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinalysis parameters of clinical laboratory test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Diastolic Blood Pressure Excursions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in Persistent Surgical Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: days in intensive care unit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total days in hospital
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: BOLD activation in neural circuits relevant to nicotine addiction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Vertebral deformity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Dose Limiting toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: oral hygiene index simplified
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-care behaviour scores
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change in code status to do-not-resuscitate/do-not-intubate
Endpoint domain: Mortality/survival
Primary endpoint: Corneal and conjunctiva staining score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in maximal oxygen consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IKDC data completion
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: KOOS data completion
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Tegner data completion
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: EQ5D data completion
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Anterior/Posterior knee translation completion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lower Limb Symmetry completion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-Operative Opioid Requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presepsine values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of completely protected individuals
Endpoint domain: Mortality/survival
Primary endpoint: Major leg wound complication
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum tolerated dose (MTD) of talazoparib combined with irinotecan
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Dose-limiting toxicities (DLT) of talazoparib combined with irinotecan
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum tolerated dose (MTD) of temozolomide combined with talazoparib
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Dose-limited toxicities (DLT) of combination therapy with temozolomide, talazoparib and irinotecan
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Change from baseline in trough Diastolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean Change in Edema Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chest Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of words remembered on Verbal learning task
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Immediate toxicity (incidence of infusion-related reactions)
Endpoint domain: Adverse events/effects
Primary endpoint: Hematopoietic toxicity (number of cycles of therapy associated with neutrophils < 0.5e9/L or platelets < 50e9/L)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence of infection (number of days with fever ≥ 38 degrees C, days of intravenous antibiotics, number of inpatient days, number of episodes of cytomegalovirus reactivation)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Eligible Women Successfully Monitored
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Occurrence of psychiatric comorbidity (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in odds of treatment of back pain between patients with psychiatric comorbidity and patients without psychiatric comorbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in pharmacological treatment in DDD's of patients with back pain with and without psychiatric comorbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Target lesion scoring at week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of lesions with scores < 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self Integration Scale (SIS) -V2
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Functional Assessment of Chronic Illness Therapy-Spiritual well being (FACIT-SP)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: The Connor-Davidson Resilience Scale (CD-RISC) (10 item version)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cortisol day curve AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: change in QoL domains
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of subjects experiencing deaths
Endpoint domain: Adverse events/effects
Primary endpoint: Number of subjects experiencing adverse events leading to discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Clinically significant changes in electrocardiogram (ECG) parameters
Endpoint domain: Adverse events/effects
Primary endpoint: BAT net glucose uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: BAT volume of metabolic activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: whole body organ glucose partitioning
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Patients Progressing to Next Chemotherapy Cycle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CNS relapse/involvement
Endpoint domain: Mortality/survival
Primary endpoint: LDL-C Target Attainment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of participants who responded to treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants discontinuing study therapy due to AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage Change in Body Weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants Achieving Body Weight Reduction ≥ 5%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: percent change in body fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Duration Effect of natalizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Significant fall in FEV1 (>20%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Need for bronchodilator treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes